OBJECTIVES: The aim of this study was to determine the efficacy and safety profile of gemcitabine plus cisplatin in patients with immunohistochemically proven unresectable cholangiocarcinoma. PATIENTS AND METHODS: Between March 2002 and December 2004, a total of 24 patients with immunohistochemically proven cholangiocarcinoma were entered in this study. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8 and cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks. RESULTS: Seventy-one cycles of treatment were given, with a median of 3 cycles (range, 2-6 cycles). Five patients had a partial response (PR), 12 patients had stable disease (SD), and 7 patients progressed during treatment. A median survival of 9.30 months (range, 6.43-12.17) was obtained hematologic and nonhematologic toxicities were generally acceptable. However, there was one treatment-related mortality caused by thrombotic thrombocytopenia purpura (TTP) associated with gemcitabine and cisplatin. CONCLUSIONS: The combination chemotherapy of gemcitabine and cisplatin had a modest effect and was a well tolerated treatment of patients with immunohistochemically proven metastatic or unresectable cholangiocarcinoma.
OBJECTIVES: The aim of this study was to determine the efficacy and safety profile of gemcitabine plus cisplatin in patients with immunohistochemically proven unresectable cholangiocarcinoma. PATIENTS AND METHODS: Between March 2002 and December 2004, a total of 24 patients with immunohistochemically proven cholangiocarcinoma were entered in this study. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8 and cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks. RESULTS: Seventy-one cycles of treatment were given, with a median of 3 cycles (range, 2-6 cycles). Five patients had a partial response (PR), 12 patients had stable disease (SD), and 7 patients progressed during treatment. A median survival of 9.30 months (range, 6.43-12.17) was obtained hematologic and nonhematologic toxicities were generally acceptable. However, there was one treatment-related mortality caused by thrombotic thrombocytopenia purpura (TTP) associated with gemcitabine and cisplatin. CONCLUSIONS: The combination chemotherapy of gemcitabine and cisplatin had a modest effect and was a well tolerated treatment of patients with immunohistochemically proven metastatic or unresectable cholangiocarcinoma.
Authors: Mirna H Farhat; Ali I Shamseddine; Ayman N Tawil; Ghina Berjawi; Charif Sidani; Wael Shamseddeen; Kassem A Barada Journal: World J Gastroenterol Date: 2008-05-28 Impact factor: 5.742
Authors: Susanna V Ulahannan; Osama E Rahma; Austin G Duffy; Oxana V Makarova-Rusher; Metin Kurtoglu; David J Liewehr; Seth M Steinberg; Tim F Greten Journal: Hepat Oncol Date: 2015-01-01
Authors: Gregory V Schimizzi; Linda X Jin; Jesse T Davidson; Bradley A Krasnick; Cecilia G Ethun; Timothy M Pawlik; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Sharon M Weber; Ahmed Salem; William G Hawkins; Steven M Strasberg; Maria B Doyle; William C Chapman; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Ryan C Fields Journal: HPB (Oxford) Date: 2017-11-21 Impact factor: 3.647